Not Signed In -
Atenolol |
Tenormin |
Clinical Trial: Compare Effectiveness of Eplerenone Vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects with HT
This study is currently recruiting patients.
Verified by Pfizer September 2005
|
Purpose
To investigate the impact of antihypertensive therapy with the selective mineralocorticoid receptor blocker, eplerenone, on small resistance artery remodeling, compared to the effect of equivalent blood pressure control achieved with a b-blocker, atenolol.
| Condition | Intervention | Phase |
|---|---|---|
| Hypertension | Drug: Eplerenone | Phase III |
MedlinePlus related topics: High Blood Pressure
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study
Official Title: A Double-Blind, Parallel Design Study to Compare the Effectiveness of Eplerenone Versus Atenolol in Reversing the Remodeling of Resistance Arteries in Subjects with Mild to Moderate Primary Hypertension
Further Study Details:
Primary Outcomes: The change from baseline to week 52 in the media/lumen ratio and the maximum % relaxation response to acetylcholine of gluteal subcutaneous resistance vessels, measured from the gluteal biopsy.
Secondary Outcomes: Will be done for both the Intent to Treat and per protocol populations, and use both the LOCF and OC methods
Expected Total Enrollment: 34
Secondary Outcomes: Will be done for both the Intent to Treat and per protocol populations, and use both the LOCF and OC methods
Expected Total Enrollment: 34
Study start: October 2003
Eligibility
Ages Eligible for Study: 30 Years - 70 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Pt with essential hypertension who have never been treated or untreated within the previous 6 months
Exclusion Criteria:
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00147563
Pfizer CT.gov Call Center 1-800-718-1021
Mona Maroun 514-693-4527 mona.maroun@pfizer.com
Mona Maroun 514-693-4527 mona.maroun@pfizer.com
Study chairs or principal investigators
Pfizer CT.gov Call Center, Study Director, Pfizer
More Information
Study ID Numbers: EPLA-0501-077
Last Updated: September 6, 2005
Record first received: September 2, 2005
ClinicalTrials.gov Identifier: NCT00147563
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 6, 2005
Record first received: September 2, 2005
ClinicalTrials.gov Identifier: NCT00147563
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
email this page
print this page
bookmark this page
feedback on this page
